Skip to content

Omron HeartGuide Review 2026: Discontinued, and What to Buy Instead

Omron HeartGuide Review 2026: Discontinued, and What to Buy Instead
November 21, 2026 ⦁ 10 min read ⦁ By Tommy Peterson ⦁ On Fitness

The Omron HeartGuide was the most interesting blood pressure wearable ever made, and it is no longer made. It was a smartwatch with a miniature inflatable cuff built into the band, so instead of estimating your blood pressure from an optical sensor it took a real oscillometric reading, the same method used in a doctor’s surgery, in about 30 seconds with your wrist held at heart level. The FDA cleared it in 2018 and it launched at $499. Omron discontinued it in 2023, stopped listing it on its US website, and never made a successor.

That matters if you were planning to buy one. New-old-stock and resale units still circulate, but there is no manufacturer warranty, no guaranteed accessory supply such as replacement cuff sleeves, and no commitment to keep the companion app working. Buying one in 2026 means buying discontinued hardware with no support behind it.

What replaced it is a mixed picture. Samsung now offers a calibrated optical blood pressure feature on its Galaxy Watch line, Apple offers a hypertension notification rather than a number, and a cuffless band from Aktiia has regulatory clearance in Europe. None of them is a direct successor, and none removes the need for a proper cuff. I pulled Tested Intelligence’s and CardiLog’s landscape reviews, Asidehouse’s validation analysis of wearable blood pressure, and the manufacturers’ current listings. Where a figure is a claim rather than a measurement, I say so.

Advertisement

At a glance

ProductBest forKey specsPrice
Omron HeartGuideHistorical reference onlyInflatable cuff in band, FDA-cleared 2018, 30-second readings, no ECGDiscontinued, $499 at launch
Samsung Galaxy WatchBest current BP watchOptical pulse wave, calibrated against an upper-arm cuff every 28 daysFrom about $350, feature included
Apple WatchBest for hypertension alertsOptical vessel analysis over 30 days, notification only, no numberFrom about $399, feature included
Aktiia Hilo bandBest cuffless optionCuffless optical, CE-marked, FDA-cleared in 2025 for spot checksNot broadly sold in the US
Huawei Watch D2Best non-US alternativeMiniature airbag in the strap, CE-MDR certifiedNot sold in the US

The HeartGuide, and why it disappeared

What it actually did

The HeartGuide solved the central problem of wrist blood pressure by refusing to be cuffless. A tiny oscillometric cuff sat in the band and inflated on demand, which is why it earned FDA clearance and a CE mark while optical estimates did not. You pressed a button, held your wrist at heart level, waited about 30 seconds and got a real systolic and diastolic reading. It also tracked activity and sleep, and it did not offer an ECG.

The mechanism was never the problem. Asidehouse’s analysis is blunt about what went wrong: the device was bulky, uncomfortable, and every reading meant a slow and conspicuous inflation cycle. At $499 it asked buyers to pay more than a validated upper-arm monitor plus a normal watch, for a product that was a mediocre smartwatch on top. Omron chose not to continue the category, and no other mainstream brand has repeated the design.

What buying one now means

Because the HeartGuide is discontinued, the practical risks are support rather than accuracy. Oscillometric measurement is the established clinical method, so a working unit should still read accurately, but you have no warranty, uncertain availability of replacement cuff sleeves, and the possibility that the app will stop working. Tested Intelligence’s verdict is the sensible one: only buy from a reputable third-party seller, and compare the used price carefully against a standard upper-arm Omron monitor, which will cost a fraction of the price and carry a warranty.

There is also a category risk. CardiLog’s October 2026 status table notes that Omron no longer lists the HeartGuide on its US website at all, so listings that still describe it as a current product are describing old stock.

What to buy instead

Samsung Galaxy Watch

Samsung’s blood pressure feature is the closest thing to a mainstream successor. It uses an optical sensor and pulse wave analysis, and it must be calibrated against an upper-arm cuff that you buy separately, then recalibrated roughly every 28 days. It gives you an on-demand reading plus a trend graph. The important caveat is regulatory: the feature was cleared in Korea in 2020 and rolled out in the United States from March 2026 as a wellness feature, not as a cleared diagnostic device. It is a useful trend tool, not a replacement for a validated cuff.

Apple Watch

Apple takes a deliberately different approach. Rather than giving you a number, the Apple Watch analyses your vessel response over 30 days and sends a notification if it sees a pattern consistent with hypertension. That notification feature received FDA clearance in 2025, but it is a screening signal and never a reading. For someone who wants to know whether to see a doctor, that is arguably more useful than a number you cannot interpret. For someone who wants to track their pressure, it is not the right product.

Aktiia Hilo band

Aktiia’s cuffless band is the most interesting option technically. It uses optical sensors and requires calibration with a supplied cuff, then monthly recalibration. The underlying Aktiia G0 technology received FDA 510(k) clearance in July 2025 as the first over-the-counter cuffless blood pressure monitor, and it is CE-marked in Europe. The catch is availability: the version sold in the United States as Hilo Core is positioned as a wellness product and is not the FDA-cleared device, so a US buyer cannot currently buy the cleared version.

Huawei Watch D2

The Huawei Watch D2 follows the HeartGuide’s original idea, with a miniature airbag built into the strap that takes a real reading. It is CE-MDR certified and sold across Europe, the UK, China and several Asian markets, but it does not hold US FDA clearance for blood pressure, so it is not a practical option for American buyers.

The validated cuff

It is worth saying plainly: if you want a number you can trust, an upper-arm cuff is still the answer. Omron’s own 3 Series monitor states that it meets the US Validated Device Listing criteria for clinical accuracy and is registered with the FDA as a medical device, and it costs a small fraction of any of the wearables here. Every expert source I read makes the same point: a wearable complements a cuff rather than replacing it.

What to do in 2026

Do not buy a HeartGuide as a current recommendation. It is discontinued stock with no support, and the money is better spent on a validated cuff plus a watch you actually want to wear.

Buy a validated upper-arm cuff if you need a number. It is cheaper, more accurate, carries a warranty and does not depend on an app that may stop working.

Buy a Samsung Galaxy Watch if you want trends and do not mind calibrating. It is the most mainstream current option, but treat the readings as wellness data and recalibrate on schedule.

Buy an Apple Watch if you want a screening alert rather than a reading. The 30-day hypertension notification is genuinely useful for deciding whether to see a doctor, and it never pretends to give you a pressure value.

Watch Aktiia rather than buying today. The technology is the most promising in the category, but the cleared version is not broadly available in the United States.

Ignore budget blood pressure smartwatches entirely. The FDA issued a safety warning in 2025 about unvalidated devices in the $20 to $80 range that produce numbers with no clinical evidence behind them. A number you cannot trust is worse than no number.

If you already own a HeartGuide

There is no need to panic. A working unit measures blood pressure accurately, and the hardware will keep doing that for as long as it holds up. The practical issues are replacement cuff sleeves, which may become harder to find, and the companion app, which depends on Omron keeping the servers and the app store listing alive. If the app stops working, you lose the history and trend view, though the watch will still take a reading.

The sensible move is to keep using it while it works, buy a spare cuff sleeve if you can find one, and start keeping a simple written or spreadsheet log of your readings so you are not dependent on the app for your own history. Replace it with a validated upper-arm cuff when it finally fails, and do not spend money repairing or replacing a discontinued device.

How to choose between the options

Start with what you actually want to know. If the question is whether your blood pressure is too high, you want a validated upper-arm cuff and a doctor, not a wearable. If the question is how your pressure trends over weeks and months, a calibrated smartwatch is reasonable. If the question is whether you should book a check-up, an Apple Watch notification is a legitimate screening prompt.

Understand the three measurement approaches. A real cuff, whether in an arm monitor or in the HeartGuide’s band, measures pressure directly and is the clinical standard. A calibrated optical estimate infers pressure from the pulse wave after you set it against a cuff, and it drifts between calibrations. A passive screen looks for a pattern over weeks and gives you an alert rather than a number. Each has a different job, and none of the optical or passive methods is a diagnosis.

Check the regulatory status in your country before you trust a number. Clearance varies by market and it changes. Samsung’s feature is cleared in Korea but sold as a wellness feature in the United States. Aktiia’s technology is cleared in Europe and by the FDA for spot checks, but the US version is not the cleared device. The HeartGuide was FDA-cleared and is now discontinued. Read the current status for your region at the time of purchase rather than relying on an older article.

Weigh the commitment against the benefit. An upper-arm cuff costs a modest amount and works for years. A smartwatch with blood pressure costs several hundred dollars and is primarily a smartwatch. A subscription band adds a recurring cost. If you only want occasional readings, the cuff wins on every measure.

Never rely on a budget device with no validation. The FDA’s 2025 warning covers the unvalidated devices that dominate the cheap end of the market, and the risk is not inaccuracy alone but the false reassurance of a plausible-looking number. If a watch claims blood pressure and does not mention clearance or calibration, walk away.

Think about the rest of the health kit. Our blood pressure smartwatch guide covers the current options, and our upper-arm monitor roundup covers the validated cuffs.

Frequently asked questions

Frequently Asked Questions

6
Is the Omron HeartGuide discontinued?

Yes. Omron discontinued the HeartGuide in 2023 and no longer lists it on its US website. Only third-party and resale stock remains, with no manufacturer warranty or guaranteed app support.

Is the Omron HeartGuide still worth buying?

No, as a current recommendation. It was genuinely innovative and its oscillometric measurement was sound, but discontinued hardware with no support is a poor buy when a validated upper-arm cuff costs a fraction of the price.

What replaced the Omron HeartGuide?

Nothing directly. Samsung offers a calibrated optical blood pressure feature on its Galaxy Watch, Apple offers a hypertension notification rather than a number, Aktiia makes a cuffless band cleared in Europe, and Huawei’s Watch D2 uses an airbag in the strap but is not sold in the US.

Can a smartwatch measure blood pressure accurately?

Only a device with a real cuff can, which is why the HeartGuide was unique. Optical estimates drift and need recalibration, and several are wellness features rather than cleared medical devices.

Is the Samsung Galaxy Watch blood pressure feature FDA cleared?

No. It was cleared in Korea in 2020 and rolled out in the United States from March 2026 as a wellness feature, so it is not a cleared diagnostic device in the US.

Does the Apple Watch give blood pressure readings?

No. It analyses vessel response over 30 days and sends a hypertension notification if it detects a pattern. That notification feature was FDA cleared in 2025.

The bottom line

The Omron HeartGuide was a genuinely clever product that solved wrist blood pressure properly with an inflatable cuff in the band, and it was discontinued in 2023 because it was bulky, conspicuous to use and expensive next to a validated cuff plus a normal watch. Do not buy one now: there is no warranty, no guaranteed app support and no accessories. Instead, buy a validated upper-arm cuff if you need a trustworthy number, a Samsung Galaxy Watch if you want trends with recalibration, or an Apple Watch if you want a hypertension alert rather than a reading. Keep an eye on Aktiia, whose cuffless band is the most promising technology in the category but is not broadly available in the United States. The honest rule is simple: a wearable complements a cuff, it does not replace one. Have you tried a blood pressure watch? Tell us in the comments.

Tommy Peterson

Tommy Peterson edits our tech, gadget, and buying-guide coverage. A hardware reviewer for 7 years and former IT systems engineer, he tear-downs and benchmarks the products he covers. His buying guides weigh real-world longevity, value, and compatibility over marketing jargon.

Leave a Comment

Your email address will not be published.